Merck
所有图片(1)

1131009

USP

胆钙化醇

United States Pharmacopeia (USP) Reference Standard

别名:
活化7-脱氢胆固醇, (+)-维生素 D3, 胆骨化醇, 活化7-脱氢胆甾醇
Empirical Formula (Hill Notation):
C27H44O
CAS号:
分子量:
384.64
Beilstein:
2339331
MDL编号:
PubChem化学物质编号:

等级

pharmaceutical primary standard

manufacturer/tradename

USP

mp

83-86 °C (lit.)

application(s)

pharmaceutical (small molecule)

格式

neat

储存温度

−20°C

SMILES string

CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]([C@]1(C)CCC/2)([H])C2=C\C=C(C[C@@H](O)CC3)/C3=C

InChI

1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1

InChI key

QYSXJUFSXHHAJI-YRZJJWOYSA-N

Gene Information

human ... VDR(7421)

正在寻找类似产品? Visit 产品对比指南

一般描述

本产品按照现行药典要求提供和指定。所有为支持本产品而提供的信息,包括 SDS 和任何产品信息小册子,均由药典颁发机构制定和发布。如需进一步的信息和支持,请访问现行药典网站。如需进一步信息和支持,请访问现行药典网站。

生化/生理作用

维生素 D 借以发挥作用的受体是配体依赖性转录因子超家族的成员。调控正常细胞和癌细胞的增殖和分化。对乳腺癌、结肠癌和前列腺癌细胞具有抗增殖和抗转移作用。肠和骨骼中的活化维生素 D 受体维持着钙的吸收和平衡。

分析说明

这些产品仅供测试和分析使用。它们不适用于人类或动物的给药,不可用于诊断、治疗或治愈任何疾病。

其他说明

USP颁布的SDS请点击此处
可能适用相应的销售限制。

象形图

Skull and crossbonesHealth hazard

警示用语:

Danger

危险分类

Acute Tox. 2 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral - STOT RE 1 Oral

储存分类代码

6.1A - Combustible, acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 2

闪点(F)

Not applicable

闪点(C)

Not applicable

分析证书

请输入批号搜索分析证书(COA)。

原产地证书 (CofO)

请输入批号搜索原产地证书(COO)。

更多文件

Quotes and Ordering

Frances C Bach et al.
Journal of cellular physiology, 229(12), 1999-2014 (2014-04-30)
The endocrine feedback loop between vitamin D3(1,25(OH)2D3) and parathyroid hormone (PTH) plays a central role in skeletal development. PTH-related protein (PTHrP) shares homology and its receptor (PTHR1) with PTH. The aim of this study was to investigate whether there is
Negar Tabatabaei et al.
The Journal of nutrition, 144(12), 1994-2001 (2014-10-25)
Whether there is a dose-dependent effect of maternal dietary cholecalciferol during pregnancy on maternal glucose tolerance is unknown. In addition, circulating osteocalcin is increased by 1,25-dihydroxyvitamin D [1,25(OH)2D] and may improve glucose homeostasis. This study was designed to test whether
C Jackson et al.
QJM : monthly journal of the Association of Physicians, 100(4), 185-192 (2007-02-20)
We evaluated the effect of supplementation with vitamin D(3) (excluding the potential effect of calcium supplementation) on the risk of fall and fracture, primarily in postmenopausal women, using a systematic literature review of MEDLINE, EMBASE, BIOSIS and the Cochrane Database
Robert Scragg et al.
Hypertension (Dallas, Tex. : 1979), 64(4), 725-730 (2014-07-02)
Previous randomized controlled trials of vitamin D supplementation and blood pressure (BP) mainly have given vitamin D for short periods (<6 months) or at low doses (400 IU per day). This study aims to determine whether long-term high-dose vitamin D
Umon Agata et al.
Journal of nutritional science and vitaminology, 59(1), 29-36 (2013-03-29)
Low calcium (Ca) intake is the one of risk factors for both bone loss and medial elastocalcinosis in an estrogen deficiency state. To examine the effect of different amounts of Ca intake on the relationship between bone mass alteration and

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门